At Isoray, we recognize the value of industry conferences, specifically when it comes to continuing your education, staying up-to-date with the latest research, and networking with industry colleagues. Our team is looking forward to once again having the opportunity to join the radiation oncologist community at the ASTRO Annual Meeting to discuss the most recent developments in cancer treatment.
Isoray was proud to be a part of yet another annual meeting for the American Brachytherapy Society (ABS) in Miami and, as we’ve had some time to process all of the stimulating conversations and unique opportunities that ABS always provides, we’d like to highlight some of our favorite moments and discussions from this year’s event.
Photo curtesy of The Boston Herald. Boston Herald Reporter Alexi Cohan recently joined Dr. Peter Orio on the “front lines” in order to learn more about brachytherapy for prostate cancer treatment. This article details the brachytherapy procedure process and the...
Transition concerns should not stop you from adding Cesium to your prostate brachytherapy practice. With a thoughtful approach to planning and the right support, you can seamlessly upgrade your prostate brachytherapy to the power of Cesium.
Prostate Cancer Research Institute: “The Importance of Knowing About All of Your Prostate Cancer Treatment Options”
“I urge newly diagnosed men to see a range of specialists before selecting treatment. After talking to a urologist, they should make independent appointments with a radiation oncologist, a medical oncologist, and a brachytherapist to ensure that they become fully...
Advantageous biological effect, Cesium-131’s short half-life, and new shielded or dynamically modulated sources: Dr. Mark Rivard’s thoughts on brachytherapy from ABS 2018
As a physicist, Dr. Mark Rivard is fascinated by brachytherapy’s ability to provide “conformal, localized” radiotherapy compared to external-beam radiation therapy for treatment of multiple cancer types.
ASTRO 2018 Insights: building community, innovating and celebrating strong data around the power of Cesium
Building community around the power of Cesium The radiation oncologist community is one of the cornerstones on which we are building the future of brachytherapy at Isoray. As such, in person engagements at the ASTRO Annual Meeting are some of our most important...
Study Shows Significantly Improved Survival Rate of Cervical Cancer Patients after Receiving Brachytherapy and EBRT
The International Journal of Radiation Oncology recently published a study titled Survival Benefit of Adjuvant Brachytherapy After Hysterectomy With Positive Surgical Margins in Cervical Cancer.
Biological effectiveness dose and convenience: Why Cesium-131 is the LDR brachytherapy isotope of choice for Dr. Bradley Prestidge.
Dr. Bradley Prestidge, MD, MS, serves as Regional Medical Director of Radiation Oncology for Bon Secours Medical Group in Norfolk, Va. During the American Brachytherapy Society 2018 Annual Meeting, Dr. Prestidge shared with us his opinion on brachytherapy’s top...
Capitalizing on the same value ASTRO provides for radiation oncologists to connect with peers in a concentrated way, we invite the entire community to visit the Isoray team at ASTRO 2018.
New long-term data show brachytherapy boost improves freedom from biochemical failure outcomes for T3 high-risk prostate cancer by more than eight percent
In a new study, radiation oncologists find that DR-BT is not only feasible, but also highly effective in men with cT3a and cT3b high-risk prostate cancer.
Three recent peer-reviewed publications reinforce the value of brachytherapy as a treatment for prostate cancer
The past 12 to 18 months have seen remarkable new scientific evidence come to light regarding the attributes and benefits of brachytherapy, including Cesium-131, for prostate cancer treatment.